Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas

Neuro-Oncology

Volumn 11, Issue 5, 2009, Pages 468-476

  Lin, Yi ^a,b   Jiang, Tao ^a,c   Zhou, Kaijia ^a   Xu, Li ^a   Chen, Baoshi ^a   Li, Guilin ^a   Qiu, Xiaoguang ^a   Jiang, Tianzi ^a,c   Zhang, Wei ^d   Song, Sonya W ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF AUTOMATION   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Glioma; IGFBP 2; Plasma surrogate biomarker; Prognosis; Recurrence

Indexed keywords

BIOLOGICAL MARKER; SOMATOMEDIN BINDING PROTEIN 2; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROSURGICAL PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70349628642     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-114     Document Type: Article

References (38)

1. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64:6892-6899. (Pubitemid 39330996)
2. Ino Y, Berwnsky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001;7:839-845. (Pubitemid 32708719)
3. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys. 2000;48:825-830. (Pubitemid 30742657)
4. Hegi Me, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
5. Gonzalgo ML, Carter HB. Update on PSA testing. J Natl Compr Canc Netw. 5:737-742.
6. Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007;8:813-821.
7. Fukuda ME, Iwadate Y, Machida T, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res. 2005;65:5190-5194. (Pubitemid 40827328)
8. Zheng P-P, Hop WC, Sillevis Smitt PAE, et al. Low-molecular weight caldesmon as a potential serum marker for glioma. Clin Cancer Res. 2005;11:4388-4392. (Pubitemid 40825628)
9. Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase- 9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006;12:5698-5704. (Pubitemid 44629598)
10. Jung CS, Foerch C, Schänzer A, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain. 2007;130(pt 12):3336-3341. (Pubitemid 350209077)
11. Fuller GN, Rhee CH, Hess KR, et al. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res. 1999;59:4228-4232.
12. Sallinen SL, Sallinen PK, Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 2000;60:6617-6622.
13. Elmlinger MW, Deininger MH, Schuett BS, et al. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology. 2001;142:1652-1658.
14. Wang H, Wang H, Zhang W, Fuller GN. Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol. 2002;12:95-107. (Pubitemid 33131366)
15. Kanety H, Madjar Y, Dagan Y, et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab. 1993;77:229-233. (Pubitemid 23206808)
16. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst. 1999;91:1758-1764. (Pubitemid 29518772)
17. Flyvbjerg A, Mogensen O, Mogensen B, et al. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab. 1997;82:2308-2313. (Pubitemid 27287605)
18. Boulle N, Logie A, Gicquel C, et al. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 1998;83:1713-1720. (Pubitemid 28501047)
19. Busund LT, Richardsen E, Busund R, et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol. 2005;58:361-366. (Pubitemid 40516165)
20. El Atiq F, Garrouste F, Remacle-Bonnet M, et al. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer. 1994;57:491-497. (Pubitemid 24173092)
21. Mohnike KL, Kluba U, Mittler U, et al. Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. Eur J Pediatr. 1996;155:81-86. (Pubitemid 126422135)
22. Juncker-Jensen A, Lykkesfeldt AE, Worm J, et al. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res. 2006;16:224-239. (Pubitemid 44296071)
23. Song SW, Fuller GN, Khan A, et al. IIp45, a novel IGFBP-2 binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc Natl Acad Sci USA. 2003;100:13970-13975.
24. Wang GK, Hu L, Fuller GN, Zhang W. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem. 2006;281:14085-14091. (Pubitemid 43848335)
25. Wang H, Wang H, Shen W, et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasionenhancing genes. Cancer Res. 2003;63:4315-4321. (Pubitemid 36950996)
26. Fukushima T, Tezuka T, Shimomura T, et al. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem. 2007;282:18634-18644. (Pubitemid 47100243)
27. Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A. 2007;104:5563-5568. (Pubitemid 47175720)
28. Dunlap SM, Celestino J, Wang H, et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A. 2007;104:11736-11741. (Pubitemid 47175082)
29. McDonald KL, O'Sullivan MG, Parkinson JF, et al. IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol. 2007;66:405-417.
30. Freije WA, Castro-Vargas Fe, Fang Z, et al. Gene expression profiling of glioma strongly predicts survival. Cancer Res. 2004;64:6503-6510. (Pubitemid 39297907)
31. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005;65:1678-1686. (Pubitemid 40478592)
32. Philips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resembles stages in neurogenesis. Cancer Cell. 2006;9:157-173. (Pubitemid 43357943)
33. Scrideli CA, Carlotti CG Jr, Mata JF, et al. Prognostic significance of co-overexpression of the eGFR/IGFBP-2/HIF-2A genes in astrocytomas. J Neurooncol. 2007;83:233-239. (Pubitemid 46952233)
34. Shariat SF, Lamb DJ, Kattan MW, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002;20:833-841.
35. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 2008;11:112-120. (Pubitemid 351676597)
36. Dawczynski K, Kauf E, Schlenvoigt D, et al. elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML. Bone Marrow Transplant. 2006;37:589-594. (Pubitemid 43378832)
37. Ho PJ, Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol. 1997;46:333-342. (Pubitemid 27174339)
38. Rechler M. Insulin-like growth factor binding proteins. Vit Horm. 1993;47:100-114.